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Abstract: The Cordyceps mushrooms have a long history as medicinal fungi. In Traditional Chinese Medicine,
Cordyceps have been used to treat several conditions including cancers for thousand of years. Extracts from both mycelium
and fruiting bodies of C. sinensis, C. militaris and other Cordyceps species showed significant anticancer activities by
various mechanisms such as, modulating immune system and inducing cell apoptosis. Some polysaccharide components
and cordycepin (3'-deoxyadenosine) have been isolated from C. sinensis and C. militaris, which acted as potent anticancer
components. This review article aims to further elucidate the importance of Cordyceps mushrooms by summarizing the
findings of some of the important research works concerning possible mechanism of anticancer activity of this mushroom.
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INTRODUCTION
There is a common saying, ‘Medicines and foods have a
common origin’. Mushrooms are a manifestation of this idea
in constituting both a nutritionally functional food and a
source of physiologically beneficial medicine. Many centuries ago, medicinal properties of mushrooms have been recognized in China, Korea and Japan. Although from ancient
times, mushrooms have been treated as a special kind of nutraceutical, they have received a remarkable interest in recent
decades. Major medicinal properties attributed to mushrooms include anticancer activity, antibiotic activity (directed against bacteria, fungi and protozoa), antiviral activity, immune response-stimulating effects, anti-hypertensive
and blood lipid lowering effects [1, 2]. Some mushrooms
have gained special consideration due to their various medicinal values in addition to nutritional importance. For example, Lentinus edodes were reported to possess anti-tumor,
antihypertensive, hypocholesterolemic and antibacterial
activities [3-6]. Ganoderma lucidum has been proved to have
anti microbial and anti-HIV effects [7, 8]. The hepatic and
renal protective effects of G. lucidum in mice were also
evaluated [9]. The beta-glucan polysaccharide of this mushroom has potential application in immune surveillance and
chemoprevention of cancer [2]. Mushrooms of Pleurotus
species (P. ostreatus, P. sajor-caju, P. florida) were reported
to have hypocholesterolemic activity in experimental rats
[10, 11].
Cordyceps mushroom is a genus of ascomycete fungi that
includes about 400 described species. All Cordyceps species
are endoparasitoids, mainly on insects and other arthropods
[12] These mushrooms have a long history as rare and exotic
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medicinal fungi. They have been a highly regarded cornerstone of traditional Chinese medicine for centuries; that apparently have a number of far reaching medicinal effects [13,
14]. Cordyceps mushrooms have been used to treat conditions including respiration and pulmonary diseases; renal,
liver, and cardiovascular diseases; hyposexuality and hyperlipidemia. It is also used in the treatment of immune disorders and as an adjunct to modern cancer therapies (chemotherapy, radiation treatment and surgery) [12]. C. sinensis
and C. militaris are the most common in use among the
Cordyceps genus.
ANTICANCER
SINENSIS

ACTIVITY

OF

CORDYCEPS

C. sinensis is a fungus that has been used for over 2000
years in China as a treatment for a variety of conditions including cancer. Many available evidences suggest that the
efficacy of C. sinensis as an anti-neoplastic therapeutic agent
is due to its role as an activator of immune responses. Extracts from both mycelium and fruiting bodies from C. sinensis influence the immune system in various ways. In a study,
water-extract from dried C. sinensis increased the median
survival time of the allogeneic mice inoculated with Ehrlich
ascites carcinoma cells (EAC) to 316% and syngeneic mice
inoculated with Meth A fibrosarcoma (Meth A) to 312% of
the control with no cytotoxic activity on either EAC or Meth
A in vitro [15]. The water extract of this mushroom has been
also proved beneficial in the prevention of tumor metastasis
in mice as an adjuvant agent in cancer chemotherapy [16].
The natural killer cells (NK) activities of mouse were both in
vivo and in vitro significantly augmented by intraperitoneal
injection of the ethanol extract of C. sinensis [17]. The ethanol-extract also significantly decreased tumor weights and
volumes in mice inoculated with Sarcoma-180 tumor cells.
The extracts were demonstrated to exhibit phagocytosis
enhancing activity as measured by carbon clearance in mice
and caused a significant increase in an acid phosphatase
2010 Bentham Open
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activity, representing lysosomal enzymes, suggesting that the
anti-tumor activity of these fungi might be related to an immuno-stimulating function [18]. The ethyl acetate extract of
C. sinensis mycelium was found to have strong anti-tumor
activity on four cancer cell lines, MCF-7 breast cancer, B16
mouse melanoma, HL-60 human premyelocytic leukemia
and HepG2 human hepatocellular carcinoma [19]. Some
specific fractions of extracts of C. sinensis, especially polysaccharides have been found to modify immune response
more precisely. The conditioned medium from the polysaccharide fraction of C. sinensis (PSCS)-stimulated blood
mononuclear cells [PSCS-MNC-CM] had an activity that
could significantly inhibit the proliferation of human leukemic U937 cells resulting in a growth inhibition rate of 7883%. Furthermore, PSCS-MNC-CM treatment induced
about 50% of the cells differentiating into mature monocytes/macrophages expressing nonspecific esterase (NSE)
and the surface antigens of CD11b, CD14 and CD 68. The
levels of interferon (IFN)-gamma, tumor necrosis factor
(TNF)-alpha and interleukin (IL)-1 were very low in normal
MNC-CM but they were greatly increased in MNC-CM prepared with PSCS stimulation. Antibody neutralization studies further revealed that the tumoricidal and differentiating
effects of PSCS-MNC-CM were mainly derived from the
elevated cytokines, especially IFN-gamma and TNF-alpha
[20]. An exopolysaccharide fraction (EPSF), prepared from
C. sinensis significantly enhanced the phagocytosis capacity
of peritoneal macrophages and proliferation ability of spleen
lymphocytes of H22 tumor (histocompatibility 22) and B16
melanoma bearing mice, as well as inhibited the tumor
growth in separate study. EPSF significantly promoted
macrophages' TNF-alpha expression and spleen lymphocytes' cytotoxicity. EPSF also significantly elevated TNFalpha and IFN-gamma mRNA expression of splenic lymphocytes and thus elevated immunocytes' activity in H22
tumor bearing mice [21, 22]. The EPSF from C. sinensis also
has inhibitory effect on oncogene expression. The c-Myc, cFos, and vascular endothelial growth factor (VEGF) levels in
the lungs and livers of EPSF-treated mice were found to be
significantly lower than those of untreated mice [23]. When
lipopolysaccharide (LPS)-activated murine macrophage cell
line R309 was exposed to the extracts C. sinensis, R309 induced significant levels of IL-1. IL-2 induction was recognized in T cell line LBRM-33 1A5 (1A5) cultures in the
presence of IL-1 and phytohemagglutinin (PHA). However,
no enhancement of IL-2 production by C. sinensis was discerned in 1A5 cultures with IL-1 and PHA, i.e., direct action
of C. sinensis was not found on IL-2 production of 1A5.
PHA-stimulated 1A5 exposed to C. sinensis induced IL-2
without IL-1 when co-cultured with LPS-activated R309 as a
source of IL-1 [24]. C. sinensis, either alone or with IFNgamma induction, increased the MHC class II antigen expression on hepatoma cell line HA22T/VGH, which makes
the host immune surveillance more effective against tumor
cells with down-regulated MHC class II antigen expression
[25]. In leukemia patients, C. sinensis augmented the NK
cell activity and also improved the CD16 marker expression
on lymphocytes and the binding capacity to K562 cells [26].
In breast cancer, the oral C. sinensis did not reduce primary
tumor growth but reduced lung metastasis occurrence in a
surgical excision model of metastatic mammary carcinoma.
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The reduction in metastases growth is supposed to due to the
effects of macrophage-derived factors on tumor cell cycle,
NK cell activation and other immunostimulating activities
[27, 28].
Although the immunomodulating activity of C. sinensis
is mainly responsible for its anticancer activity, it is not so
simply described and only exact mechanism. Directly or
indirectly many other metabolic and genetic pathways are
responsible. Extensive research works have been done to
evaluate the mechanism of anticancer activity of C. sinensis
and the most significant mechanism has been found to influence apoptosis. In a study, the ethyl acetate extract of mycelium of C. sinensis induced the characteristic apoptotic
symptoms in human premyelocytic leukemia cells (HL-60),
DNA fragmentation and chromatin condensation. The activation of caspase-3 and the specific proteolytic cleavage of
poly ADP-ribose polymerase were detected during the
course of apoptosis induction. These results suggest that this
extract inhibited cancer cell proliferation by inducing cell
apoptosis [29]. The involvement of caspase-8 with caspase-3
was also found in C. sinensis induced apoptosis in MA-10
mouse Leydig tumor cells [30]. Components from Cordyceps induce tumor cell apoptosis through both extrinsic and
intrinsic pathways. Two new epipolythiodioxopiperazines,
named gliocladicillins A and B, from Cordyceps-colonizing
fungi inhibited growth of HeLa, HepG2 and MCF-7 tumor
cells by arresting the cell cycle at G(2)/M phase and induced
apoptosis through up-regulation of expression of p53, p21,
and cyclin B and activation of caspases-8, -9 and -3 [31].
Furthermore, EPSF of C. sinensis decreased the levels of
Bcl-2 in the lungs and livers [22]. The antitumor activity of
C. sinensis by inducing apoptosis was also found in human
colorectal (HT-29 and HCT 116), hepatocellular (Hep 3B
and Hep G2) carcinoma cells [32] and human oral squamous
cancer cell line (OEC-M1) [33]. Interestingly, Tang et al.
[34] reported that C. sinensis reduced Angiotensin II induced
NRK-52E cell apoptosis, which may be part of its mechanism of the protective effects on hypertensive renal damage.
The antioxidant activity of C. sinensis components is also
responsible for its anticancer property. The ethanolic extract
of C. sinensis was found to have inhibitory effect on lipid
peroxidation and protective effect on 4-nitroquinoline oxidetriggered DNA lesion in V79 hamster cells [35]. The polysaccharide component of C. sinensis has been found to inhibit the tumor growth of H22-bearing mice by modulating
the antioxidant enzymes activity such as enhancing superoxide dismutase (SOD) activity of liver, brain and serum as
well as glutathione peroxidase (GPx) activity of liver and
brain in tumor-bearing mice [36]. Wang et al. [32] reported
the free radical scavenging activity of C. sinensis. As free
radicals are responsible for oxidative damage of apoptotic
genes, by scavenging free radicals, C. sinensis protects apoptotic genes and induces the apoptosis of cancer cells.
ANTICANCER
MILITARIS

ACTIVITY

OF

CORDYCEPS

The mushroom C. militaris has been used for a long time
in eastern Asia as a nutraceutical and in traditional Chinese
medicine as a therapeutic agent for cancer patients. C. militaris has been found good for inhibiting the growth of tumor,
prolonging the survival period of mice implanted with S180
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sarcoma cells and inhibiting the growth and metastasis of
Lewis pneumonic cancer in the implanted mice [37]. Water
extract of C. militaris inhibited growth of human umbilical
vein endothelial cells (HUVEC) and human sarcoma cell line
HT1080. This mushroom extract also reduced metalloproteinase 2 (mmp2) gene expression in HT1080 and basic fibroblast growth factor (bFGF) gene expression in HUVECs
[38]. Recently, a cytotoxic protease was purified from
the dried fruiting bodies of C. militaris, which exhibited
cytotoxicity against human breast and bladder cancer cells
[39].
Like C. sinensis, the most significant anticancer mechanism of C. militaris was found by inducing cell apoptosis. In
a study, Park et al. [40] observed that the aqueous extract of
C. militaris (AECM) inhibited cell growth of human leukemia U937 cells by morphological change and apoptotic cell
death such as formation of apoptotic bodies and DNA fragmentation. They also observed the down-regulation of antiapoptotic gene bcl-2 expression and proteolytic activation of
caspase-3 in AECM-treated U937 cells. But AECM did not
affect the pro-apoptotic gene bax expression and activity of
caspase-9. The hot water extract of C. militaris was also
found to induce apoptosis in the human premyelocytic leukemia HL-60 cells and the activation of caspase-3 and the
specific proteolytic cleavage of Poly ADP-ribose polymerase
(PARP) were detected during the course of apoptosis [41]. In
addition to the activation of caspase-3, the AECM-induced
apoptosis may relate to the inactivation of Akt (an oncogene)
in human breast cancer MDA-MB-231 cells [42]. In another
study, the growth inhibition and apoptosis induction by the
water extract of C. militaris (WECM) treatment in human
lung carcinoma A549 cells were found associated with the
induction of Fas expression, catalytic activation of caspase8, and Bid cleavage. Activation of caspases, downregulation
of anti-apoptotic gene bcl-2 expression, and upregulation of
pro-apoptotic Bax protein were also observed in WECMtreated cancer cells. In addition, WECM exerted a dosedependent inhibition of telomerase activity via down-regulation of human telomerase reverse transcriptase (hTERT),
c-Myc and Sp1 expression. The data indicated that WECM
induced the apoptosis of A549 cells through a signaling cascade of death receptor-mediated extrinsic and mitochondriamediated intrinsic caspase pathways and diminishing the
telomerase activity through the inhibition of hTERT transcriptional activity [43].
ANTICANCER ACTIVITY OF OTHER CORDYCEPS
SPECIES
Three different polysaccharide-peptide complexes
(PPCs) were produced by submerged mycelial culture of a
rare entomopathogenic fungus Cordyceps sphecocephala
and their anticancer activities were investigated in human
hepatocarcinoma (HepG2) and neuroblastoma (SK-N-SH)
cells. In this study, PPC-induced apoptosis of both cancer
cells was found which was associated with intracellular
events including DNA fragmentation, activation of caspase3, and modulation of Bcl-2 and Bax and no cytotoxicity
against normal cells was reported [44].
A water-insoluble extracellular glucan (CO-1) was isolated from the precipitate formed on incubation of the culture
filtrate of Cordyceps ophioglossoides and this CO-1 strongly
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inhibited the growth of Sarcoma 180 solid-type tumor [45].
The effects of protein-bound polysaccharide (SN-C) extracted from C. ophioglossoides on the growth of transplanted allogeneic and syngeneic murine tumors were studied and it was found that SN-C given by intraperitoneal administration suppressed the growth of sarcoma-180 transplanted subcutaneously in mice. SN-C also showed a significant cytocidal effect on cultured tumor cells but did not affect delayed-type hypersensitivity (DTH) in normal mice
[46]. A protein-bound galactosaminoglycan (CO-N) was
isolated from SN-C of C. ophioglossoides. When given intraperitoneally to mice, CO-N inhibited the proliferation of
sarcoma 180 cells inoculated into the peritoneal cavity and
exhibited a marked life-prolonging effect against ascitic tumors such as Ehrlich carcinoma. CO-N also showed an inhibitory effect against solid Ehrlich carcinoma when given
intratumorally and significantly inhibited the growth of a
syngeneic solid tumor (MM46 mammary carcinoma) upon
intravenous administration at a low dose [47].
CORDYCEPIN: AN ANTICANCER AGENT FROM
CORDYCEPS SPECIES
Cordycepin, or 3'-deoxyadenosine, is a derivative of the
nucleoside adenosine, differing from adenosine by the
absence of oxygen in the 3' position of its ribose part.
Cordycepin was isolated from the water extract of C.
sinensis [33, 48]. Later the major component of the butanol
fraction of C. militaris was also identified as cordycepin by
high performance liquid chromatography [49]. Because
cordycepin is similar to adenosine, RNA polymerase cannot
discriminate between the two and when incorporated into a
growing RNA molecule, cordycepin prevents further elongation, thus producing a prematurely terminated RNA molecule [50].
Orally administered cordycepin inhibited B16-BL6
melanoma cell growth in mice with no adverse effects [48].
Further study demonstrated that cordycepin inhibited the
proliferation of B16-BL6 cells by stimulating adenosine A3
receptors followed by the Wnt signaling pathway, including
GSK-3beta activation and cyclin D1 inhibition [51]. Cordycepin markedly inhibited the phosphorylation of Akt and p38
in dose-dependent manners in LPS-activated macrophage.
Moreover, cordycepin suppressed TNF-alpha expression,
Ikappa B alpha phosphorylation and translocation of nuclear
factor-kappa B (NF-kappa B) [49]. Cordycepin-induced
apoptosis is also reported. In MA-10 cells (a mouse Leydig
tumor cell line), cordycepin induced DNA fragmentation,
declined the percentage of G1 and G2/M phase cells, increased the percentages of subG1 phase cells suggesting
cordycepin induced MA-10 cell apoptosis. Moreover, western blotting analysis showed that cordycepin induced
caspase-9, caspase--3 and caspase--7 protein expressions, but
not caspase-8 [52]. In another study, cordycepin significantly
induced cell apoptosis in OEC-M1 human oral squamous
cancer cells [23]. It was also suggested that the effect of
cordycepin on the growth of tumor cells was significantly
related to the metabolism-associated protein expression induced by cordycepin [53]. Platelet aggregation induced by
cancer cells is an indispensable step for hematogenic metastasis and it was showed that cordycepin had an inhibitory
effect on hematogenic metastasis of B16-F1 melanoma cells
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via blocking of ADP-induced platelet aggregation in vivo
[54]. A novel molecular mechanism for the anti-tumor effects of cordycepin in two different bladder cancer cell lines,
5637 and T-24 cells has been revealed by Lee et al. [55].
They reported that cordycepin treatment during cell-cycle
progression resulted in significant growth inhibition, which
was largely due to G2/M-phase arrest and resulted in an upregulation of p21WAF1 expression, independent of the p53
signaling pathway. Moreover, treatment with cordycepin
induced phosphorylation of JNK (c-Jun N-terminal kinases).
Blockade of JNK function using SP6001259 (JNK-specific
inhibitor) and small interfering RNA (si-JNK1) rescued
cordycepin-dependent p21WAF1 expression, inhibited cell
growth and decreased cell cycling proteins.
Derivatives of cordycepin have also showed anticancer
activity. In an experiment, 1-O-Acetyl-2,5-di-O-p-chlorobenzoyl-3-deoxy-D-ribofuranose, derived from cordycepin
was coupled with trimethylsilylated derivatives of N4propionylcytosine, N4-p-toluoyl-5-fluorocytosine and 5fluorouracil in the presence of trimethylsilyl trifluoromethanesulfonate (TMS-triflate) to give fully acylated
nucleosides. Selective removal of the N4-propionyl group
of these nucleosides by treatment with hydrazine hydrate
gave 2',5'-di-O-p-chlorobenzoyl-3'-deoxycytidine, deamination of which with sodium nitrite in trifluoroacetic acid afforded 2',5'-di-O-p-chlorobenzoyluridine in good yield. The
acylated nucleosides and 2',5'-di-O-p-chlorobenzoyluridine
were saponified to give free 3'-deoxycytidine, 5-fluoro-3'-deoxycytidine, 3'-deoxyuridine, and 5-fluoro-3'-deoxyuridine,
respectively. These 3'-deoxyribonucleosides were then examined for growth-inhibitory effects on mouse leukemic
L5178Y cells, and their IC50 (inhibitory concentration 50)
values were found 1.8, 33, 6.5, and 18 (microgram/ml) respectively [56]. Other nucleotide derivatives also exist which
showed anticancer activities, such as, forodesine (also
known as Immucillin H; IUPAC name: 7-[(2S,3S,4R,5R)3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl]-1,5-dihydropyrrolo[2,3-e]pyrimidin-4-one) is a inhibitor of purine nucleoside phosphorylase, which is recognized as a potential
target for the treatment of patients with T-cell malignancies
and also B-cell chronic lymphocytic leukemia [57, 58].
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